Phase Ii/Iii Clinical Results Of Il-15r[Alpha]Fc Superagonist N-803 With Bcg In Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer (Nmibc) Carcinoma In Situ (Cis) Patients.

Karim Chamie,Sam Chang,Mark L. Gonzalgo,Eugene V. Kramolowsky,Wade J. Sexton,Sandeep K. Reddy,Paul Bhar,Chad Garner,Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 30|浏览5

暂无评分

摘要

510Background: Patients with NMIBC CIS unresponsive to BCG have limited treatment options. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL-15RαFc) that promotes...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要